|
Cobimetinib Clinical Trials
7 actively recruiting trials across 4 locations
Also known as: COTELLIC, Cotellic, GDC 0973, GDC-0973, GDC0973 +5 more
Pipeline
Early 1: 1Phase 1: 1Phase 2: 4Phase 2/3: 1
Top Sponsors
- OHSU Knight Cancer Institute1
- National Cancer Institute (NCI)1
- Helsinki University Central Hospital1
- Genentech, Inc.1
- City of Hope Medical Center1
Indications
- Cancer7
- Lung Cancer3
- Erdheim-Chester Disease2
- Haematological Malignancy2
- Thyroid Carcinoma, Anaplastic1
Other2 trials
Duarte, California2 trials
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
City of Hope Comprehensive Cancer Center
Phase 2
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2
Phoenix, Arizona1 trial
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phoenix Children's Hospital
Phase 2
Atlanta, Georgia1 trial
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Emory University Hospital/Winship Cancer Institute
Phase 1
Portland, Oregon1 trial
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Early 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.